CA3118281C - Therapie de photobiomodulation pour traiter une affection degenerative de la retine et/ou du nerf optique - Google Patents
Therapie de photobiomodulation pour traiter une affection degenerative de la retine et/ou du nerf optique Download PDFInfo
- Publication number
- CA3118281C CA3118281C CA3118281A CA3118281A CA3118281C CA 3118281 C CA3118281 C CA 3118281C CA 3118281 A CA3118281 A CA 3118281A CA 3118281 A CA3118281 A CA 3118281A CA 3118281 C CA3118281 C CA 3118281C
- Authority
- CA
- Canada
- Prior art keywords
- light
- eye
- pbmt
- retina
- optic nerve
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001328 optic nerve Anatomy 0.000 title claims abstract description 61
- 210000001525 retina Anatomy 0.000 title claims abstract description 44
- 230000003412 degenerative effect Effects 0.000 title claims description 32
- 238000002560 therapeutic procedure Methods 0.000 title abstract description 19
- 230000007246 mechanism Effects 0.000 claims description 6
- 229920002799 BoPET Polymers 0.000 claims description 4
- 239000005041 Mylar™ Substances 0.000 claims description 4
- 210000004279 orbit Anatomy 0.000 claims description 3
- 101100520094 Methanosarcina acetivorans (strain ATCC 35395 / DSM 2834 / JCM 12185 / C2A) pcm2 gene Proteins 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 230000004044 response Effects 0.000 abstract description 19
- 208000003435 Optic Neuritis Diseases 0.000 abstract description 18
- 238000011282 treatment Methods 0.000 abstract description 17
- 201000006417 multiple sclerosis Diseases 0.000 abstract description 9
- 230000003287 optical effect Effects 0.000 abstract description 5
- 206010029240 Neuritis Diseases 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 14
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 9
- 201000002491 encephalomyelitis Diseases 0.000 description 9
- 230000002438 mitochondrial effect Effects 0.000 description 9
- 230000004382 visual function Effects 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000012014 optical coherence tomography Methods 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000004770 neurodegeneration Effects 0.000 description 5
- 210000001747 pupil Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000016192 Demyelinating disease Diseases 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229940124625 intravenous corticosteroids Drugs 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 206010012305 Demyelination Diseases 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 210000002592 gangliocyte Anatomy 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000004898 mitochondrial function Effects 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 201000004981 autoimmune optic neuritis Diseases 0.000 description 2
- 230000003376 axonal effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004065 mitochondrial dysfunction Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000004126 nerve fiber Anatomy 0.000 description 2
- 210000003733 optic disk Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229950003937 tolonium Drugs 0.000 description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108050008072 Cytochrome c oxidase subunit IV Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150101057 PBA1 gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 101710119418 Superoxide dismutase [Mn] Proteins 0.000 description 1
- 101710202572 Superoxide dismutase [Mn], mitochondrial Proteins 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 238000002571 electroretinography Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000002118 histological preservation Methods 0.000 description 1
- 238000012766 histopathologic analysis Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000006577 protective pathway Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 229940080150 systane Drugs 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000000857 visual cortex Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F9/009—Auxiliary devices making contact with the eyeball and coupling in laser light, e.g. goniolenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/0622—Optical stimulation for exciting neural tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
- A61F2009/00863—Retina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
- A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
- A61N2005/0645—Applicators worn by the patient
- A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head
- A61N2005/0648—Applicators worn by the patient the applicator adapted to be worn on the head the light being directed to the eyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0651—Diodes
- A61N2005/0652—Arrays of diodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/067—Radiation therapy using light using laser light
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Ophthalmology & Optometry (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Radiation-Therapy Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une thérapie de photobiomodulation (PBMT) pouvant être appliquée à l'il pour traiter la névrite optique, un symptôme de la sclérose en plaques (MS). La lumière de PBMT peut être dirigée dans l'il, indépendamment de la position de l'il, par un dispositif qui comprend un réseau de dispositifs de distribution de lumière et une lentille de dissipateur thermique. Le dispositif peut être placé à proximité de l'il pour diriger la lumière dans l'il. La lumière peut présenter une ou plusieurs longueurs d'onde de 400 à 1 100 nm et peut être appliquée selon au moins un mode choisi parmi un mode de fonctionnement pulsé, un mode de fonctionnement continu et un mode de fonctionnement super-pulsé, par l'intermédiaire du dispositif source de lumière et en direction du muscle squelettique. Le signal lumineux est appliqué pendant une durée suffisante pour stimuler une réponse photothérapeutique dans la rétine et/ou le nerf optique. La PBMT appliquée de cette manière procure un traitement non invasif, sûr et efficace de la névrite optique.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752467P | 2018-10-30 | 2018-10-30 | |
| US62/752,467 | 2018-10-30 | ||
| PCT/US2019/058754 WO2020092495A1 (fr) | 2018-10-30 | 2019-10-30 | Thérapie de photobiomodulation pour traiter une affection dégénérative de la rétine et/ou du nerf optique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3118281A1 CA3118281A1 (fr) | 2020-05-07 |
| CA3118281C true CA3118281C (fr) | 2022-06-14 |
Family
ID=70463986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3118281A Active CA3118281C (fr) | 2018-10-30 | 2019-10-30 | Therapie de photobiomodulation pour traiter une affection degenerative de la retine et/ou du nerf optique |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11253722B2 (fr) |
| EP (1) | EP3873597A4 (fr) |
| AU (1) | AU2019369419B2 (fr) |
| BR (1) | BR112021008362A2 (fr) |
| CA (1) | CA3118281C (fr) |
| MX (1) | MX2021005114A (fr) |
| WO (1) | WO2020092495A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021005114A (es) * | 2018-10-30 | 2021-05-27 | Multi Radiance Medical | Terapia de fotobiomodulacion para tratar una enfermedad degenerativa de la retina y/o del nervio optico. |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030002297A1 (en) | 2001-06-26 | 2003-01-02 | Nemtsev Igor Z. | Light bracelet and brace |
| US20130079759A1 (en) * | 2005-04-14 | 2013-03-28 | Robert S. Dotson | Ophthalmic Phototherapy Device and Associated Treatment Method |
| WO2008131343A1 (fr) * | 2007-04-19 | 2008-10-30 | Mergenet Medical, Inc. | Contrôle temporel en photothérapie |
| IL184218A0 (en) | 2007-06-26 | 2007-10-31 | Zidkiyahu Simenhaus | Photo-magnetic radiation device |
| US8922898B2 (en) * | 2008-09-04 | 2014-12-30 | Innovega Inc. | Molded lens with nanofilaments and related methods |
| US9763827B2 (en) * | 2013-04-30 | 2017-09-19 | Tear Film Innovations, Inc. | Systems and methods for the treatment of eye conditions |
| GB201315836D0 (en) * | 2013-09-05 | 2013-10-23 | Polyphotonix Ltd | Medical apparatus and method |
| DE102013017586A1 (de) | 2013-10-17 | 2015-05-07 | Turbolite Vertriebs Gmbh | BEHANDLUNGSGERÄT für magnetfeldunterstützte BESTRAHLUNGSTHERAPIEN |
| US10137311B2 (en) * | 2014-07-17 | 2018-11-27 | Troy HUDSON | Light therapy glasses and mobile application |
| WO2016040534A1 (fr) | 2014-09-09 | 2016-03-17 | LumiThera, Inc. | Dispositifs, systèmes et procédés de photothérapie à plusieurs longueurs d'onde pour le traitement non invasif de tissu endommagé ou malade |
| US20160067087A1 (en) * | 2014-09-09 | 2016-03-10 | LumiThera, Inc. | Wearable devices and methods for multi-wavelength photobiomodulation for ocular treatments |
| EP3028742A1 (fr) | 2014-12-05 | 2016-06-08 | Mikropis Holding d.o.o. Zalec | Dispositif combiné portable de thérapie magnétique et par la lumière |
| US20170106201A1 (en) | 2015-07-01 | 2017-04-20 | Btl Holdings Limited | Combination of magnetic and electromagnetic treatment method |
| US20170128736A1 (en) | 2015-11-09 | 2017-05-11 | Multi Radiance Medical | System and method for preventing muscle fatigue |
| BR112020002313B1 (pt) * | 2017-08-02 | 2022-04-19 | Multi Radiance Medical | Sistema e método para direcionar luz ao olho de um paciente |
| MX2021005114A (es) * | 2018-10-30 | 2021-05-27 | Multi Radiance Medical | Terapia de fotobiomodulacion para tratar una enfermedad degenerativa de la retina y/o del nervio optico. |
-
2019
- 2019-10-30 MX MX2021005114A patent/MX2021005114A/es unknown
- 2019-10-30 EP EP19880588.9A patent/EP3873597A4/fr not_active Withdrawn
- 2019-10-30 AU AU2019369419A patent/AU2019369419B2/en active Active
- 2019-10-30 BR BR112021008362-6A patent/BR112021008362A2/pt unknown
- 2019-10-30 CA CA3118281A patent/CA3118281C/fr active Active
- 2019-10-30 WO PCT/US2019/058754 patent/WO2020092495A1/fr unknown
- 2019-10-30 US US17/289,778 patent/US11253722B2/en active Active
-
2021
- 2021-12-23 US US17/560,793 patent/US11724123B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3873597A1 (fr) | 2021-09-08 |
| EP3873597A4 (fr) | 2022-01-05 |
| AU2019369419B2 (en) | 2021-07-01 |
| US11724123B2 (en) | 2023-08-15 |
| BR112021008362A2 (pt) | 2021-08-03 |
| CA3118281A1 (fr) | 2020-05-07 |
| MX2021005114A (es) | 2021-05-27 |
| US11253722B2 (en) | 2022-02-22 |
| US20210308482A1 (en) | 2021-10-07 |
| WO2020092495A1 (fr) | 2020-05-07 |
| AU2019369419A1 (en) | 2021-06-03 |
| US20220184412A1 (en) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Saltmarche et al. | Significant improvement in cognition in mild to moderately severe dementia cases treated with transcranial plus intranasal photobiomodulation: case series report | |
| Caldieraro et al. | Transcranial and systemic photobiomodulation for major depressive disorder: A systematic review of efficacy, tolerability and biological mechanisms | |
| US10632325B2 (en) | Method, system and apparatus for non-invasive neurostimulation therapy of the brain | |
| CA3071842C (fr) | Systeme et procede pour diriger la lumiere dans l'oeil d'un patient | |
| Quirk et al. | Near-infrared photobiomodulation in an animal model of traumatic brain injury: improvements at the behavioral and biochemical levels | |
| US20080033412A1 (en) | System and method for convergent light therapy having controllable dosimetry | |
| US11724123B2 (en) | Photobiomodulation therapy to treat a degenerative condition of the retina and/or the optic nerve | |
| CA3081264C (fr) | Therapie de photobiomodulation pour ameliorer la sclerose en plaques | |
| US11638833B2 (en) | Reducing light polution in photobiomodulation therapy of a patients eye | |
| Caldieraro et al. | Transcranial and systemic photobiomodulation for the enhancement of mitochondrial metabolism in depression | |
| Ho | Wireless Light Delivery for Photodynamic Therapy | |
| US20210059858A1 (en) | Methods for preventing and treating ocular disease | |
| Iennaco | The effect of photobiomodulation on cerebral blood flow | |
| Johnstone | The potential of light therapy in Parkinson’s |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210429 |
|
| EEER | Examination request |
Effective date: 20210429 |
|
| EEER | Examination request |
Effective date: 20210429 |